Trial Profile
Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Acute myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 28 Dec 2015 New trial record